K-Ras and mitochondria: Dangerous liaisons

It is well documented that the K-RAS oncogene efficiently transforms non-malignant cells, and there is some evidence for the role of mitochondria in this process. Now Peng Huang and colleagues show that K-Ras induction results early on in mitochondria assuming the phenotype consistent with the so-called Warburg effect, i.e., increased glycolysis and attenuated oxidative phosphorylation. Thus the K-Ras protein capable of swift induction of phenotypic changes typical of cancer cells, yet these changes are reversible, and for cells to irreversibly reach their full malignant potential a much longer K-Ras expression is required, implicating mitochondria in the longer-term effects of the oncogene.

[1]  M. Barbacid,et al.  Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. , 1984, Science.

[2]  W. Wheaton,et al.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.

[3]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[4]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[5]  D. Levy,et al.  Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation , 2009, Science.

[6]  A. Balmain,et al.  Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene , 1983, Nature.

[7]  G. Garcia-Manero,et al.  K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis , 2011, Cell Research.

[8]  C. Marshall,et al.  Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1 , 1983, Nature.

[9]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[10]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[11]  Emma Saavedra,et al.  The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. , 2010, Molecular aspects of medicine.

[12]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[13]  F. Domann,et al.  α-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II , 2008, Oncogene.

[14]  B. Zhivotovsky,et al.  Mitochondria in cancer cells: what is so special about them? , 2008, Trends in cell biology.

[15]  J. Neuzil,et al.  Anticancer drugs targeting the mitochondrial electron transport chain. , 2011, Antioxidants & redox signaling.